RENEO PHARMACEUTICALS INC (RPHM)

RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023

RPHM stock results show that Reneo Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reneo Pharmaceuticals (NASDAQ:RPHM) just reported results for the fourth quarte...

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Reneo stock plunges 84% as company shuts down lead program (NASDAQ:RPHM)

Reneo Pharmaceuticals (RPHM) stock plunged 84% after the company said it was shutting down its lead drug program following a failed study. Read more here.

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction...

Reneo Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for RPHM

William Blair starts Reneo at outperform, cites mitochondrial disorders drug (NASDAQ:RPHM)

William Blair initiated coverage of Reneo (RPHM) with an outperform rating, citing the potential of its drug candidate for primary mitochondrial myopathies. Read more here.

Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

Topline data results from the pivotal STRIDE study are expected in December 2023

Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

Topline data results from the pivotal STRIDE study are expected in December 2023

Reneo Pharmaceuticals Becomes Oversold (RPHM)

Reneo Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for RPHM

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the...

Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the...

Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

Topline data results from the STRIDE study are expected in December 2023

Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

Topline data results from the STRIDE study are expected in December 2023

Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

IRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the...

HC Wainwright starts Reneo at buy, sees possible 2025 launch for lead drug (RPHM)

HC Wainwright started coverage of Reneo (RPHM) with a buy rating, citing the prospects of its lead drug mavodelpar in the treatment of primary mitochondrial myopathies, or PMM.

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to...

Investors Grab RPHM 20.6% Lower Than Its Secondary Stock Offering

Benzinga's Top Ratings Upgrades, Downgrades For July 3, 2023